DGAP-News

Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care reports fourth quarter and full year 2014 results - Seite 2

revenue increased by 151% to $395 million. Dialysis product revenue
increased by 8% to 236 million compared to the fourth quarter of 2013.

International revenue increased by 5% to $1,422 million (+15% at constant
currency). Organic revenue growth was 7%. Health Care revenue increased by
12% to $682 million (+26% at constant currency). Dialysis product revenue
decreased by 1% to $740 million (+6% at constant currency).

Earnings

Operating income (EBIT) increased from $661 million in the fourth quarter
of 2013 to $663 million in the fourth quarter of 2014. Operating income for
North America for the fourth quarter of 2014 was $493 million, an increase
of 9% as compared to the fourth quarter of 2013. In the International
segment, operating income for the fourth quarter of 2014 increased by 2% to
$278 million as compared to $274 million in the fourth quarter of 2013.

Net interest expense for the fourth quarter of 2014 was $117 million,
compared to $98 million in the fourth quarter of 2013.

Income tax expense was $143 million for the fourth quarter of 2014, which
translates into an effective tax rate of 26.2%. This compares to income tax
expense of $171 million and a tax rate of 30.4% for the fourth quarter of
2013. The tax rate was affected favorably by the resolution of challenged
deductions for civil settlement payments taken in prior years.
Net income attributable to shareholders of Fresenius Medical Care AG & Co.
KGaA for the fourth quarter of 2014 was $335 million, a decrease of 4%
compared to $349 million for the fourth quarter of 2013.

Basic earnings per share (EPS) for the fourth quarter of 2014 was $1.11, a
decrease of 5% compared to the corresponding number for the fourth quarter
of 2013. The weighted average number of shares outstanding for the fourth
quarter of 2014 was approximately 303.3 million shares, compared to
approximately 301.0 million shares for the fourth quarter of 2013. The
increase in shares outstanding resulted from stock option exercises during
2014.

Cash flow

In the fourth quarter of 2014, the company generated $588 million in net
cash provided by operating activities, representing 14% of revenue, almost
unchanged compared to the corresponding figure of last year ($ 589
million).

A total of $282 million was spent for capital expenditures, net of
disposals. Free cash flow was $306 million compared to $355 million in the
fourth quarter of 2013.